Decreased need for RRT in liver transplant recipients after pretransplant treatment of hepatorenal syndrome-type 1 with terlipressin.
Journal
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
ISSN: 1527-6473
Titre abrégé: Liver Transpl
Pays: United States
ID NLM: 100909185
Informations de publication
Date de publication:
09 Oct 2023
09 Oct 2023
Historique:
received:
23
05
2023
accepted:
25
09
2023
pubmed:
6
10
2023
medline:
6
10
2023
entrez:
6
10
2023
Statut:
aheadofprint
Résumé
Hepatorenal syndrome-acute kidney injury (HRS-AKI), a serious complication of decompensated cirrhosis, has limited therapeutic options and significant morbidity and mortality. Terlipressin improves renal function in some patients with HRS-1, while liver transplantation (LT) is a curative treatment for advanced chronic liver disease. Renal failure post-LT requiring renal replacement therapy (RRT) is a major risk factor for graft and patient survival. A post hoc analysis with a 12-month follow-up of LT recipients from a placebo-controlled trial of terlipressin (CONFIRM; NCT02770716) was conducted to evaluate the need for RRT and overall survival. Patients with HRS-1 were treated with terlipressin plus albumin or placebo plus albumin for up to 14 days. RRT was defined as any type of procedure that replaced kidney function. Outcomes compared between groups included the incidence of HRS-1 reversal, the need for RRT (pretransplant and posttransplant), and overall survival. Of the 300 patients in CONFIRM (terlipressin n = 199; placebo, n = 101), 70 (23%) underwent LT alone (terlipressin, n = 43; placebo, n = 27) and 5 had simultaneous liver-kidney transplant (terlipressin, n = 3, placebo, n = 2). The rate of HRS reversal was significantly higher in the terlipressin group compared with the placebo group (37%, n = 16 vs. 15%, n = 4; p = 0.033). The pretransplant need for RRT was significantly lower among those who received terlipressin ( p = 0.007). The posttransplant need for RRT, at 12 months, was significantly lower among those patients who received terlipressin and were alive at Day 365, compared to placebo ( p = 0.009). Pretransplant treatment with terlipressin plus albumin in patients with HRS-1 decreased the need for RRT pretransplant and posttransplant.
Identifiants
pubmed: 37801553
doi: 10.1097/LVT.0000000000000277
pii: 01445473-990000000-00264
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 American Association for the Study of Liver Diseases.
Références
Flamm SL, Wong F, Ahn J, Kamath PS. AGA Clinical Practice Update on the evaluation and management of acute kidney injury in patients with cirrhosis: Expert review. Clin Gastroenterol Hepatol. 2022;20:2707–2716.
Runyon BA Practice Guidelines Committee. American Association for the Study of Liver Diseases (AASLD). Management of adult patients with ascites due to cirrhosis. Hepatology. 2004;39:841–856.
Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996;23:164–176.
Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62:968–974.
Angeli P, Garcia-Tsao G, Nadim MK, Parikh CR. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol. 2019;71:811–822.
Gines P, Sola E, Angeli P, Wong F, Nadim MK, Kamath PS. Hepatorenal syndrome. Nat Rev Dis Primers. 2018;4:23.
Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008;134:1360–1368.
Piano S, Gambino C, Vettore E, Calvino V, Tonon M, Boccagni P, et al. Response to terlipressin and albumin is associated with improved liver transplant outcomes in patients with hepatorenal syndrome. Hepatology. 2021;73:1909–1919.
Cavallin M, Kamath PS, Merli M, Fasolato S, Toniutto P, Salerno F, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology. 2015;62:567–574.
Jamil K, Pappas SC, Devarakonda KR. In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V(1) and V(2). J Exp Pharmacol. 2018;10:1–7.
Wong F, Pappas SC, Curry MP, Reddy KR, Rubin RA, Porayko MK, et al. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. N Engl J Med. 2021;384:818–828.
Administration USFD. FDA approves treatment to improve kidney function in adults with hepatorenal syndrome. In. US Food & Drug Administration: US Food & Drug Administration; 2022.
Nadim MK, Genyk YS, Tokin C, Fieber J, Ananthapanyasut W, Ye W, et al. Impact of the etiology of acute kidney injury on outcomes following liver transplantation: Acute tubular necrosis versus hepatorenal syndrome. Liver Transpl. 2012;18:539–548.
Wong F, Leung W, Al Beshir M, Marquez M, Renner EL. Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation. Liver Transpl. 2015;21:300–307.
Bahirwani R, Campbell MS, Siropaides T, Markmann J, Olthoff K, Shaked A, et al. Transplantation: Impact of pretransplant renal insufficiency. Liver Transpl. 2008;14:665–671.
Singal AK, Kuo YF, Reddy KR, Bataller R, Kwo P. Healthcare burden and outcomes of hepatorenal syndrome among cirrhosis-related hospitalisations in the US. Aliment Pharmacol Ther. 2022;56:1486–1496.
Cullaro G, Verna EC, Lai JC. Association between renal function pattern and mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2019;17:2364–2370.
Tatum JM, Barmparas G, Ko A, Dhillon N, Smith E, Margulies DR, et al. Analysis of survival after initiation of continuous renal replacement therapy in a surgical intensive care unit. JAMA Surg. 2017;152:938–943.
Sharma P, Goodrich NP, Zhang M, Guidinger MK, Schaubel DE, Merion RM. Short-term pretransplant renal replacement therapy and renal nonrecovery after liver transplantation alone. Clin J Am Soc Nephrol. 2013;8:1135–1142.
Chok KS, Fung JY, Chan SC, Cheung TT, Sharr WW, Chan AC, et al. Outcomes of living donor liver transplantation for patients with preoperative type 1 hepatorenal syndrome and acute hepatic decompensation. Liver Transpl. 2012;18:779–785.
Kulkarni AV, Arab JP, Premkumar M, Benitez C, Tirumalige Ravikumar S, Kumar P, et al. Terlipressin has stood the test of time: Clinical overview in 2020 and future perspectives. Liver Int. 2020;40:2888–2905.
Wong F, Pappas SC, Reddy KR, Vargas H, Curry MP, Sanyal A, et al. Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute-on- chronic liver failure. Aliment Pharmacol Ther. 2022;56:1284–1293.
Curry MP, Vargas HE, Befeler AS, Pyrsopoulos NT, Patwardhan VR, Jamil K. Early treatment with terlipressin in patients with hepatorenal syndrome yields improved clinical outcomes in North American studies. Hepatol Commun. 2023;7:e1307.
Reddy KR, Weinberg EM, Gonzelez SA, Izzy M, Simonetto DA, Frederick RT, et al. Safety and efficacy of continuous infusion terlipressin in AKI-HRS: The INFUSE Study. In Hepatology: AASLD. 2022;76:S1171–S1173.
Kwong AJ, Ebel NH, Kim WR, Lake JR, Smith JM, Schladt DP, et al. OPTN/SRTR 2021 Annual Data Report: Liver. Am J Transplant. 2023;23:S178–S263.
O’Grady JG, Lake J. Death with low MELD scores and possible implications for organ allocation. Am J Transplant. 2017;17:2238–2239.
Mazumder NR, Atiemo K, Daud A, Kho A, Abecassis M, Levitsky J, et al. Patients with persistently low MELD-Na scores continue to be at risk of liver-related death. Transplantation. 2020;104:1413–1418.
Oden-Brunson H, McDonald MF, Godfrey E, Keeling SS, Cholankeril G, Kanwal F, et al. Is liver transplant justified at any MELD score? Transplantation. 2023;107:680–692.